A recent genome-wide association study performed by Lee et al. in HCC patients receiving sorafenib has reported a relationship between genetic variants in SLC15A2, encoding for peptide transporter 2 (PEPT2), and sorafenib responsiveness. This evidence concerns the gene SLC15A2 and hepatocellular carcinoma.